Barr confirms patent challenge

Metropolitanjury · Jul 30th, 2008, 06:22 AM

Barr Pharmaceuticals Inc. confirmed today that its Pomona-based subsidiary, Barr Laboratories Inc., has challenged four patents held by Amgen Inc. for its Sensipar drug, used by dialysis patients to treat side-effects of the treatment.

Barr said it filed an Abbreviated New Drug Application with the Food and Drug Administration on March 10, the first date the agency could accept such an application for the kidney drug.

On Monday, Amgen, along with patent partners Brigham and Women’s Hospital Inc. and NPS Pharmaceuticals Inc., filed suit against Barr and Israeli drug-maker Teva Pharmaceutical Industries Ltd. for planning to sell generic Sensipar before the expiration of patent protection.

Sensipar recorded $377 million in U.S. sales during the 12 months ending May, Barr said.

Teva, the world’s largest generic-drug maker, is buying Montvale, N.J.-based Barr for $9 billion, the companies said jointly earlier this month.

Shares of Barr were down fractionally in noontime trading to $65.81 a share.

By Ms.Bobby Aanand, Metropolitan Jury

Jul 30th, 2008, 06:22 AM	#1
Metropolitanjury Veteran Member Last Online: Jul 31st, 2008 06:18 AM Join Date: Jun 2008 Posts: 98	Barr confirms patent challenge Barr Pharmaceuticals Inc. confirmed today that its Pomona-based subsidiary, Barr Laboratories Inc., has challenged four patents held by Amgen Inc. for its Sensipar drug, used by dialysis patients to treat side-effects of the treatment. Barr said it filed an Abbreviated New Drug Application with the Food and Drug Administration on March 10, the first date the agency could accept such an application for the kidney drug. On Monday, Amgen, along with patent partners Brigham and Women’s Hospital Inc. and NPS Pharmaceuticals Inc., filed suit against Barr and Israeli drug-maker Teva Pharmaceutical Industries Ltd. for planning to sell generic Sensipar before the expiration of patent protection. Sensipar recorded $377 million in U.S. sales during the 12 months ending May, Barr said. Teva, the world’s largest generic-drug maker, is buying Montvale, N.J.-based Barr for $9 billion, the companies said jointly earlier this month. Shares of Barr were down fractionally in noontime trading to $65.81 a share. By Ms.Bobby Aanand, Metropolitan Jury

Thread Tools	Search this Thread
Show Printable Version Email this Page	Search this Thread: Advanced Search
Display Modes	Rate This Thread
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode	Rate This Thread:

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
Should I Challenge This?	jcbrenna	Other Criminal Law Matters	1	Nov 21st, 2008 09:09 AM
Patent Office finds voice, calls for software patent sanity	Metropolitanjury	Law News	0	Jul 30th, 2008 06:20 AM
Consumer Groups File Appeal on Challenge of Human Stem Cell Patent Held By WARF	Metropolitanjury	Law News	0	Jul 19th, 2008 06:32 AM
Incorrect name on jaywalking ticket - can I challenge?	Unregistered	Other Criminal Law Matters	1	Dec 14th, 2007 04:02 PM
U.S. Patent vs. International Patent	Unregistered	International Law Issues	1	Dec 13th, 2006 04:13 PM